inauguration_biopharmaceutical_production_facility_vienna inauguration_biopharmaceutical_production_facility_vienna The state-of-the-art biopharmaceutical production facility in Vienna is the single largest investment in the company's history.
Bluetongue disease Bluetongue disease The bluetongue virus is a viral disease that affects ruminants' health. It doesn't affect humans, but it is a threat to animals.
Boehringer Olaf Scholz break ground for innovation center Boehringer Olaf Scholz break ground for innovation center Boehringer Ingelheim and German Chancellor Olaf Scholz lay the foundation stone for 285 million EUR innovation center
Phase 1 start of treatment for Geographic Atrophy patients Phase 1 start of treatment for Geographic Atrophy patients Boehringer initiates Phase 1 evaluation of BI 771716 a treatment for preserving vision of people living with geographic atrophy (GA)
Fredrik Gruenenfelder Fredrik Gruenenfelder , Lead Risk Management Physician, talks about his career journey, from veterinarian to playing a key role in keeping patients safe.
FIBRONEER™ Phase III program initiated FIBRONEER™ Phase III program initiated FIBRONEER™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor
Edda Dankmeyer Edda Dankmeyer Edda Dankmeyer is our Lead of Sustainable Development Communications. She tells us where her passion for sustainability comes from, why she joined us, and how sustainable development can be a key differentiator for the company.
Heart Diseases in humans and animals Heart Diseases in humans and animals Humans and animals are more alike than different. Having a heart disease can affect us similarly, and the way to prevent it can work for all as well.
Small Cell Lung Cancer Small Cell Lung Cancer Discover more about small cell lung cancer, including its symptoms and treatment options.
FDA- HFpEF-breakthrough-designation-EMPEROR-preserved FDA- HFpEF-breakthrough-designation-EMPEROR-preserved U.S. FDA issues Breakthrough Therapy Designation for the treatment of adults with heart failure with preserved ejection fraction
preserved-heart-failure-treatment-FDA-US-approval preserved-heart-failure-treatment-FDA-US-approval US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction
preserved-heart-failure-treatment-approval-europe preserved-heart-failure-treatment-approval-europe preserved-heart-failure-treatment-approval-europe
emperor-preserved-heart-failure-toplineresults emperor-preserved-heart-failure-toplineresults Positive, top-line results announced from the EMPEROR-Preserved Phase III trial in adults with heart failure with preserved ejection fraction
emperor-reduced-chmp-positive-opinion emperor-reduced-chmp-positive-opinion CHMP issues positive opinion for the treatment of adults with heart failure with reduced ejection fraction
Equestrian sports horse health awareness Alex Hua Tian Equestrian sports horse health awareness Alex Hua Tian Together with Olympian trailblazer and eventer Alex Hua Tian, we educate about equine health in China.
Health equity for underserved communities Health equity for underserved communities Introducing initiatives that improve access to healthcare for underserved communities
SIRPα Cancer Immunology Research SIRPα Cancer Immunology Research Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.
A global production network against supply shortages A global production network against supply shortages The production of medicines is a complex process. We use our global production network to respond to increasing demand.
AUROBAC's Strategy & Pipeline Against Severe Infections & Resistance AUROBAC's Strategy & Pipeline Against Severe Infections & Resistance AUROBAC THERAPEUTICS presents strategy and growing pipeline to tackle severe infections and antimicrobial resistance
Partnership with IBM to accelerate new antibody therapies Partnership with IBM to accelerate new antibody therapies Boehringer Ingelheim collaborates with IBM to advance generative AI and foundation models for therapeutic antibody development
Survodutide Phase III study weight loss Survodutide Phase III study weight loss Boehringer Ingelheim to advance survodutide into three global Phase III studies in obesity
Rabies wildlife 5 things to know Rabies wildlife 5 things to know Rabies in wildlife - 5 things to know to protect yourself and your pet
Agreement-to-acquire-Labor-Dr.-Merk Agreement-to-acquire-Labor-Dr.-Merk Boehringer Ingelheim to acquire Labor Dr. Merk & Kollegen to strengthen its next generation cancer immunology program
RE-LY-trial-publication-10-year-anniversary RE-LY-trial-publication-10-year-anniversary Boehringer Ingelheim recognises the contribution made in the decade since the RE-LY® trial publication by patients, HCPs and researchers
Big hearts united to help animals in Ukraine Big hearts united to help animals in Ukraine Veterinaries volunteer at the Polish-Ukrainian border to help welcome Refugees and their animals. Refugees don’t rest until their animals are safe.